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Beta interferon (IFN-b) is a cytokine with potent immunomodulatory properties and has been
described as a promising therapeutic molecule for the treatment of rheumatoid arthritis (RA).
IFN-b was previously overexpressed intra-articularly using an adenoviral vector in rats with
adjuvant arthritis (AA) as a model of RA. This effect was powerful, albeit transient due to the vector
chosen. Therefore, in the context of pre-clinical development, a delivery vector optimized for
intra-articular gene transfer, recombinant adeno-associated virus type 5 (rAAV5), was selected.
To exert an optimal effect, protein production should parallel the course of the disease. For
this reason, the gene for IFN-b was placed under the control of an inflammation-responsive
[nuclear factor (NF)-kB] promoter. After intra-articular injection of the rAAV5 constructs in rats
with AA, local transcription of the transgene and production of the IFN-b protein was found,
leading to a pronounced and sustained effect on paw swelling when the expression was under
the control of the NF-kB-responsive promoter. Additionally, a significant beneficial effect was
observed on proteoglycan depletion and erosions. Thus, intra-articular overexpression of IFN-b
using a rAAV5 vector exhibits potential as an innovative therapy for the treatment of RA.
An improved understanding of the pathophysiology of
rheumatoid arthritis (RA) has led to the development of
several potential new therapeutic approaches based on
either cytokines or cytokine inhibitors. Beta interferon
(IFN-b) is a potent cytokine that exerts a variety of anti-
inflammatory and chondroprotective effects in various
animal models of RA (Tak et al., 1999; Triantaphyllopoulos
et al., 1999; van Holten et al., 2004). In addition, the
absence of IFN-b was recently shown to exacerbate arthritis
in IFN-b2/2 mice by activation of osteoclasts and stromal
cells (Treschow et al., 2005). However, in patients, subcuta-
neous injections of recombinant IFN-b three times a week
did not appear to be clinically effective (van Holten et al.,
2005). We speculated that the short half-life of IFN-b
protein in vivo and the route of administration may have
contributed to insufficiently high levels in the joints for a
therapeutic effect.
The feasibility of overexpressing IFN-b by intra-articular
delivery of gene therapy vectors was therefore investigated
in an animal model of RA (Adriaansen et al., 2006a). In
this proof of principle study, an adenoviral vector encoding
IFN-b under the control of the cytomegalovirus (CMV)
promoter injected into the joints of arthritic rats was
observed to induce a robust therapeutic effect, illustrated
by a decrease in paw swelling, a significant shift towards an
anti-inflammatory cytokine profile in the synovial tissue
and pronounced effects on bone degradation. However,
this effect was transient, lasting only 8 days. Adenoviral
vector delivery can induce a strong host immune response,
leading to elimination of transduced cells (Bessis et al.,
2004), while the CMV major immediate-early (IE) promo-
ter can also be silenced in vivo, resulting in a rapid decrease
of transgene expression (Brooks et al., 2004; van de Loo
et al., 2004).
We selected an alternative vector system, derived from
adeno-associated virus (AAV) to test in pre-clinical develop-
mental studies. AAV vectors are associated with low
immunogenicity, minimal toxicity and are able to transduce
both dividing and non-dividing cells (Adriaansen et al.,
2006b). Previously, recombinant AAV (rAAV) vectors,
packaged in serotype 5 capsids (rAAV5) have been shown
to efficiently transduce synovial tissue and they gave rise to
stable, long-term intra-articular transgene expression
(Adriaansen et al., 2005). In the study presented here, the
rat IFN-b gene was inserted between the inverted terminal
repeats of AAV2 and the DNA was packaged in AAV5
capsids. Both the CMV major IE and a nuclear factor (NF)-
kB-responsive promoter were used. Using the latter
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as NF-kB is highly activated in the synovium during inflam-
mation (Tak & Firestein, 2001). We have validated this
promoter in vitro for its specific NF-kB inducibility (data not
shown). In addition, we attempted to boost IFN-b produc-
tion by inclusion of an intron in the expression construct.
Briefly, cDNA encoding the rat IFN-b gene (kindly pro-
vided by Dr C. Kaynor, Biogen Idec, Cambridge, MA,
USA) including its signal peptide was amplified by PCR
(Fwd: 59-CCCGGATCCACCATGGCCAACAGGTGGAC-
CCTCCACATTGCGTTCCTGCTGTGCTTCTCCACCA-
CTGCCCTCCCATCGACTACAAGCAGCTCCAG-39; Rev:
59-CCCGGATCCTCAGTTCTGGAAGTTTCTATTAAG-
TC-39) and cloned into the BamHI site of the pDC315-
shuttle plasmid (Microbix Biosystems). This gene was
subsequently inserted between NheI and XhoI sites in the
pAAV2-CMV-shuttle plasmid (Applied Viromics). To
insert an intron downstream of the rat IFN-b gene,
pDC315 was digested with NheI and SalI and ligated into
a pCI (Promega) plasmid containing the intron. The gene
cassette, including the intron, was subsequently excised with
SnaBI and SalI and inserted in the pAAV2-CMV-shuttle
plasmid. To clone the IFN-b gene under the control of the
NF-kB-induciblepromoter,theCMVpromoterwasreplaced
by an NF-kB-responsive promoter. The NF-kB motif was
derived from the human immunodeficiency virus long
terminal repeat and was cloned into pGmCMV (Promega)
using restriction enzymes NheIa n dXhoI, forming the
construct pGNL2. The vector pGNL6 containing six repeats
of the NF-kB motif was constructed by digesting pGNL2
with NheIa n dXhoI and further ligation with the phos-
phorylated NF-kB oligonucleotides. Thereafter, the NF-kB
promoter was digested from pGNL6 by NcoIa n dXbaIt o
replace the CMV promoter in the previously obtained
pAAV2-CMV-IFN-b plasmid. All constructs were confirmed
by sequencing.
rAAV5 vectors were subsequently produced at the UNC
Vector Core (Chapel Hill, NC, USA), as described pre-
viously (Xiao et al., 1998). Briefly, AAV vectors were gener-
ated using the triple transfection protocol and purified
using a sequential process of nuclei isolation, density-
gradient centrifugation and heparin-sulfate affinity column
chromatography. Subsequently, vectors were titrated by
dot-blot analysis.
All together, three rAAV5 vectors containing the rat
IFN-b gene, rAAV5.CMV-IFN-b, rAAV5.NF-kB-IFN-b
and rAAV5.CMV-IFN-b-intron were constructed; an
empty vector consisting of only the CMV-shuttle vector
without the transcription cassette served as a control. Using
these vectors, an animal experiment was conducted. Rats
(n57 per group) were immunized at the base of their tail
with 1 mg Mycobacterium tuberculosis H37RA (Difco) in
0.1 ml mineral oil on day 0 (Tak et al., 2001). Paw swelling
was usually observed by days 10–11 and measured daily
by water displacement plethysmometry. The right ankle
joints were injected intra-articularly on day 12 after
immunization in animals anaesthetized with isoflurane.
The skin was disinfected with ethanol and 5610
10 viral
molecules (vm) of rAAV5.NF-kB-IFN-b, rAAV5.CMV-IFN-
b,r A A V 5 . C M V - I F N - b-intron or empty vector serving as a
control was injected anterolaterally into the right ankle joints
in a total volume of 50 ml saline using a 31-gauge needle on a
glass syringe (Nguyen et al.,1 9 9 8 ) .T h r e ew e e k sl a t e r ,t h e
animals were sacrificed and hind joints were collected. Hind
ankle joints were snap frozen in liquid nitrogen, pulverized
using a pestle and mortar, and homogenized in Trizol
Reagent (100 mg ml
21; Invitrogen) using a tissue homo-
genizer. For both reverse transcriptase and real-time PCR
(n53 per group), total RNA was isolated from the aqueous
phaseaccordingtothemanufacturer’sinstructions.RNAwas
dissolved in DEPC-treated water; the quality was checked by
gel electrophoresis and quantified by spectrophotometry.
cDNA was synthesized using the iScript cDNA Synthesis
kit (Bio-Rad) and 1 mg RNA according to the instruction
manual. RT-PCR amplification mixtures (25 ml) contained
25 ng template cDNA, 26 SYBR Green I Supermix (12.5 ml;
Bio-Rad) and 300 nM IFN-b Fwd (59-CGTTCCTGCTGT-
GCTTCTC-39) and Rev (59-TGTAACTCTTCTCCATCTG-
TGAC-39) primers. Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was used as an internal reference gene
(Fwd: 59-ATGCCATCACTGCCACTC-39;R e v :5 9-GGGT-
AGGAACACGGAAGG-39). Reactions were run on a Mini-
Opticon real-time thermal cycler (Bio-Rad). The thermal
profile consisted of one cycle at 95uC for 3 min followed by
40 cycles at 95 uC for 15 s and 59uC for 45 s. Each assay
included (in duplicate): a standard curve of five serial dilu-
tions of IFN-b and GAPDH cDNA, a no-template control
and 25 ng samplecDNA. Each runwas followedbya melting
curve. Single control normalization for internal control gene
and correction for primer efficiency were calculated as
described earlier (Vandesompele et al., 2002).
For immunohistochemical detection of rat IFN-b protein
in synovial tissue (n54 per group), arthritic paws were
fixed in 4% buffered formalin and decalcified in 15%
EDTA. The paws were then embedded in paraffin and
5 mm sagittal serial sections of the hind ankle joints
were cut. Primary IgG antibody (rabbit anti-rat IFN-b;
Biomedical Laboratories) was incubated overnight at
4uC, followed by incubation with horseradish peroxidase
(HRP)-conjugated swine anti-rabbit immunoglobulin
(Dako) for 30 min. For control sections, the primary
antibody was omitted. HRP activity was detected using
hydrogen peroxide as the substrate and 3-amino-9-
ethylcarbazole (Sigma) as the dye. Sections were briefly
counterstained with Mayer’s hemalum solution. The signal
was subsequently quantified by digital image analysis. Six
randomly selected fields within each section were chosen
for digitizing the intensity of the signal. These images were
acquired on an Olympus microscope, captured using a
Charged Coupled Device video camera (Sony) and digitized
with a PV100 multimedia 16-bit colour video digitizer
card. In the resultant colour images, the area of positive
staining and the mean optical density (MOD) were
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et al., 2001). The MOD is proportional to the cellular
concentration of protein. The integrated optical density
(IOD) is equal to the MOD multiplied by the area of
positive staining.
Sections were also stained with Safranin O-fast green to
determine the loss of proteoglycans. Safranin O staining
was scored using a semiquantitative scoring system (0–3),
where 0 represents no loss of proteoglycans, while a score
of 3 indicates complete loss of staining for proteoglycans
(Joosten et al., 1999; van Holten et al., 2004). Differences
between groups were determined by the Kruskal–Wallis
test, followed by a Mann–Whitney U-rank-sum test.
P,0.05 was considered statistically significant. All analyses
were done using SPSS version 11.5 (SPSS).
Fig. 1. Evaluation of rAAV5-mediated IFN-b gene delivery in AA in rats. Relative IFN-b mRNA levels in joint tissue. Total RNA
was extracted from crushed joints 24 days after intra-articular injection and cDNA was synthesized. RT-PCR (a) and real-time
PCR (b) were performed using specific primers for the IFN-b gene. Ct values were normalized to GAPDH levels and expressed
as fold increase compared with matched controls mean±SEM. All treated animals significantly overexpressed the transgene in
their joints, rAAV5.NF-kB-IFN-b gave rise to the highest IFN-b mRNA levels (*P,0.05; n53 per group) and intra-articular IFN-b
protein production after local gene therapy. Rat joints were collected 24 days after injecting the virus, decalcified and
embedded in paraffin (n54 per group). Sections were immunohistochemically stained for rat IFN-b (c) and quantified by digital
image analysis (d). Protein production was highest in rAAV5.NF-kB-IFN-b injected animals, followed by the rAAV5.CMV-IFN-b
group. Control and rAAV5.CMV-IFN-b-intron injection did not result in increased IFN-b production.
rAAV5.IFN-b gene therapy inhibits arthritis in rats
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animals treated with AAV recombinants. Injection of
rAAV5.NF-kB-IFN-b resulted in the highest levels of
IFN-b mRNA, whereas in animals treated with the control
vector only low amounts of endogenous IFN-b mRNA
could be detected by both RT-PCR (Fig. 1a) and real-
time PCR (Fig. 1b). IFN-b protein could clearly be
detected by immunohistochemical staining (Fig. 1c) and
was quantified as described above by computer-assisted
image analysis. Injection of rAAV5.NF-kB-IFN-b resulted
in the highest synovial production of IFN-b, followed by
the rAAV5.CMV-IFN-b injected animals. Control and
rAAV5.CMV-IFN-b-intron treated animals showed only
endogenous levels of IFN-b (Fig. 1d).
Interestingly, a pronounced reduction in paw swelling was
shown after a single intra-articular injection of rAAV5.NF-
kB-IFN-b, resulting in sustained amelioration of arthritis
until the end of the experiment. In contrast, both
rAAV5.CMV-IFN-b and rAAV5.CMV-IFN-b-intron did
not lead to significant improvement in paw thickness
compared with control animals (Fig. 2a). This is most
likely because of the lower intra-articular IFN-b produc-
tion compared with the rAAV5.NF-kB-IFN-b injected
animals, where the promoter is continuously driving
expression during inflammation. In addition to the effect
on inflammation we investigated the effect on cartilage
degradation by Safranin O staining (Fig. 2b), which
showed significantly less proteoglycan loss and erosions
in treated animals as determined by a semiquantitative
scoring system (Joosten et al., 1999; van Holten et al.,
2004) (Fig. 2c). Taken together, we demonstrated that
the combined use of a low-immunogenic rAAV5 vector
and a disease inducible NF-kB-responsive promoter allows
prolonged therapeutic effects in an animal model for RA.
Thus, application of IFN-b in this context may represent a
promising and innovative therapy for the intra-articular
treatment of RA.
Fig. 2. Therapeutic effect of local rAAV5-mediated IFN-b gene therapy. Effect of IFN-b on paw swelling. To evaluate the effects
of IFN-b gene therapy on clinical arthritis, seven rats per group were injected intra-articularly (i.a.) into the right ankle joint with
the therapeutic vector or empty vector (control) (510
10 vm per joint) on day 12 after arthritis induction. (a) Paw swelling was
measured by water displacement plethysmometry. A significant decrease in paw swelling was found in animals treated with the
NF-kB driven construct (*P,0.05). (b, c) Cartilage damage in rats with AA treated with local IFN-b gene therapy. (b) After 24
days, paws were paraffin embedded and stained with Safranin O to detect changes in proteoglycan loss. (c) Stainings were
semiquantitatively scored on a scale from 0 to 3, ranging from fully stained cartilage to destained cartilage or complete loss of
articular cartilage by two independent observers. A significant reduction in cartilage destruction was seen in animals injected
with rAAV5.NF-kB-IFN-b and rAAV5.CMV-IFN-b compared with the control (P,0.05).
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